2023
Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms
Puzo C, Tormey C, Rinder H, Siddon A. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms. Transplantation And Cellular Therapy 2023, 29: 459.e1-459.e4. PMID: 37062510, DOI: 10.1016/j.jtct.2023.04.005.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationStem cell transplantationDonor chimerismCell transplantationNGS testingPost allogeneic stem cell transplantationMeasurable residual diseaseNext-generation sequencingAcute myeloid leukemiaConditioning regimenRelated donorsMyelodysplastic syndromeResidual diseaseValidation cohortMyeloid leukemiaMyeloid neoplasmsNGS panelLogistic regressionPatientsChimerismSignificant predictorsCharacteristic curveTransplantationRegimenConservative threshold
2015
Pathology Consultation on Gene Mutations in Acute Myeloid Leukemia
Ziai JM, Siddon AJ. Pathology Consultation on Gene Mutations in Acute Myeloid Leukemia. American Journal Of Clinical Pathology 2015, 144: 539-554. PMID: 26386075, DOI: 10.1309/ajcp77zfpuqgygwy.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid leukemiaGene mutationsTypes of AMLNormal acute myeloid leukemiaAggressive chemotherapy regimensMinimal residual diseaseChemotherapy regimensDisease courseImmunophenotypic featuresResidual diseaseTherapeutic regimensPatient prognosisPrognostic informationTherapeutic implicationsAML classificationIndividualized approachPathology consultationFatal diseasePrognosisHeterogeneous groupRelevant gene mutationsDiseaseLaboratory evaluationRegimens